Article
Validation and Clinical Utility of a Pan-Cancer Circulating Tumor DNA Assay as a First-Approach Test.
The Journal of molecular diagnostics : JMD - 1 Dec 2025
Kanwar Nisha, Campion Michael B, Schneider Amber R, Milosevic Dragana, Sosa Carlos, Wojcik Antonina A, Halling Kevin C, Rumilla Kandelaria M, Lo Ying-Chun, Niu Zhiyv, Geiersbach Katherine B, DiGuardo Margaret A, Kipp Benjamin R, Zheng Gang
Abstract excerpt
The feasibility of circulating tumor (ct)-DNA assays in first-approach pan-cancer genomic profiling is not well established. Furthermore, low ctDNA levels limit assay sensitivity, which challenges adaptation to clinical genomic profiling. In this study, a 33-gene next-generation sequencing-based ctDNA panel was validated, and these issues were investigated using real-world clinical data. The cohorts included 123...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.